PF-Atlas › Clinical Trials › NCT03486236

A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects

VX-440 · Phase 1

Registry ID

NCT03486236

Phase

Phase 1

Status

Completed

Drug / intervention

VX-440

Sponsor

Vertex Pharmaceuticals Incorporated

Start

2016-07-20

Enrollment

Locations

About this trial

This study evaluated the safety and pharmacokinetics of multiple ascending doses of VX-440 in combination with tezacaftor/ivacaftor (TEZ/IVA) (triple combination \[TC\]) administered for 13 days to healthy male and female subjects

View NCT03486236 on ClinicalTrials.gov →

Explore related

All VX-440 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT03486236 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.